These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10047507)

  • 1. NMR spectroscopy in structure-based drug design.
    Roberts GC
    Curr Opin Biotechnol; 1999 Feb; 10(1):42-7. PubMed ID: 10047507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exchange-transferred NOE spectroscopy and bound ligand structure determination.
    Post CB
    Curr Opin Struct Biol; 2003 Oct; 13(5):581-8. PubMed ID: 14568612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMR structure-based drug design.
    Fesik SW
    J Biomol NMR; 1993 May; 3(3):261-9. PubMed ID: 7689377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NMR studies of ligand binding.
    Nitsche C; Otting G
    Curr Opin Struct Biol; 2018 Feb; 48():16-22. PubMed ID: 29017071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of NMR screening techniques to the pharmaceutical target Checkpoint kinase 1.
    Lancelot N; Piotto M; Theret I; Lesur B; Hennig P
    J Pharm Biomed Anal; 2014 May; 93():125-35. PubMed ID: 24280017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solution structure and ligand-binding site of the carboxy-terminal SH3 domain of GRB2.
    Kohda D; Terasawa H; Ichikawa S; Ogura K; Hatanaka H; Mandiyan V; Ullrich A; Schlessinger J; Inagaki F
    Structure; 1994 Nov; 2(11):1029-40. PubMed ID: 7881903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMR techniques for characterization of ligand binding: utility for lead generation and optimization in drug discovery.
    Moore JM
    Biopolymers; 1999; 51(3):221-43. PubMed ID: 10516573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NMR analysis of carbohydrate-protein interactions.
    Angulo J; Rademacher C; Biet T; Benie AJ; Blume A; Peters H; Palcic M; Parra F; Peters T
    Methods Enzymol; 2006; 416():12-30. PubMed ID: 17113857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The solution structure of Abl SH3, and its relationship to SH2 in the SH(32) construct.
    Gosser YQ; Zheng J; Overduin M; Mayer BJ; Cowburn D
    Structure; 1995 Oct; 3(10):1075-86. PubMed ID: 8590002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand-target interactions: what can we learn from NMR?
    Carlomagno T
    Annu Rev Biophys Biomol Struct; 2005; 34():245-66. PubMed ID: 15869390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of NMR and EPR methods to the study of RNA.
    Qin PZ; Dieckmann T
    Curr Opin Struct Biol; 2004 Jun; 14(3):350-9. PubMed ID: 15193316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NMR-based analysis of protein-ligand interactions.
    Cala O; Guillière F; Krimm I
    Anal Bioanal Chem; 2014 Feb; 406(4):943-56. PubMed ID: 23591643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of ligand binding modes in weak protein-ligand complexes using sparse NMR data.
    Mohanty B; Williams ML; Doak BC; Vazirani M; Ilyichova O; Wang G; Bermel W; Simpson JS; Chalmers DK; King GF; Mobli M; Scanlon MJ
    J Biomol NMR; 2016 Nov; 66(3):195-208. PubMed ID: 27778134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMR in drug design.
    Harner MJ; Mueller L; Robbins KJ; Reily MD
    Arch Biochem Biophys; 2017 Aug; 628():132-147. PubMed ID: 28619618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding site identification and structure determination of protein-ligand complexes by NMR a semiautomated approach.
    Ziarek JJ; Peterson FC; Lytle BL; Volkman BF
    Methods Enzymol; 2011; 493():241-75. PubMed ID: 21371594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of backbone motions in ligand binding to the c-Src SH3 domain.
    Wang C; Pawley NH; Nicholson LK
    J Mol Biol; 2001 Nov; 313(4):873-87. PubMed ID: 11697910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Ligand-Induced Protein Chemical Shift Perturbations To Determine Protein-Ligand Structures.
    Yu Z; Li P; Merz KM
    Biochemistry; 2017 May; 56(18):2349-2362. PubMed ID: 28406291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CORCEMA refinement of the bound ligand conformation within the protein binding pocket in reversibly forming weak complexes using STD-NMR intensities.
    Jayalakshmi V; Rama Krishna N
    J Magn Reson; 2004 May; 168(1):36-45. PubMed ID: 15082247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Nuclear Overhauser Effect in the lead identification process.
    Leone M; Freeze HH; Chan CS; Pellecchia M
    Curr Drug Discov Technol; 2006 Jun; 3(2):91-100. PubMed ID: 16925517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear magnetic resonance studies of flexible opiate conformations at monoclonal antibody binding sites. Quantitative interproton distances obtained from comparing theoretical and experimental transferred nuclear Overhauser enhancement: correlation with antibody sequence.
    Glasel JA
    J Mol Biol; 1989 Oct; 209(4):747-61. PubMed ID: 2585508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.